PUBLIC COMPANY
save$SRPTSarepta Therapeutics, Inc.
$SRPT17.50-0.40%Cambridge, MA, USupdated 1d ago
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
community read0 votes
pipeline
5
marketed
4
phase 3
0
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(5)
pipeline depth5 products
4Marketed1Unknown
Marketed
casimersen
Duchenne Muscular Dystrophy
Marketeddelandistrogene moxeparvovec
Duchenne Muscular Dystrophy
Marketedeteplirsen
Duchenne Muscular Dystrophy
Marketedgolodirsen
Duchenne Muscular Dystrophy
Dystrophin pre-mRNA
drugAMONDYS 45
1 INDICATIONS AND USAGE AMONDYS 45 is indicated for the t…
Dystrophin pre-mRNA
Upcoming
Recent(90d)
earnings (1)
Active trials
- phase2Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
- phase2Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
- —An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
- phase4Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
- phase1A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
- phase1A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- phase3A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
- phase3A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week sho…biospace · 2d ago
- Epicrispr lands $90M to advance epigenetic editing drug for rare muscle diseaseThe startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.biopharma_dive · 1mo ago
- Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, moreThe FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outl…biospace · 2mo ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 2mo ago
- STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executiveThe beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.stat · 2mo ago
- Building a workforce engine for biomanufacturingOhio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.fiercebiotech · 2mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 3mo ago
- STAT+: Next-gen Duchenne drug from Entrada disappointsA next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.stat · 5mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that